The accident that changed everything In 2008, after an older diabetes drug got tangled up in a heart-risk scare, the FDA started demanding that every new diabetes medication prove it did not raise the risk of heart attacks and strokes
It belongs to a novel class of drugs known as triple agonists, meaning it simultaneously targets three hormone receptors: glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon receptors
Instead, slowly and gently depress the plunger, letting the water run down the side of the glass to pool at the bottom
Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes
Research Overview Understanding the Triple-Receptor Mechanism Retatrutide is the first clinically advanced peptide engineered for balanced agonism at three class B G protein-coupled receptors simultaneously: the glucagon-like peptide-1 receptor (GLP-1R), the glucose-dependent insulinotropic polypeptide receptor (GIPR), and the glucagon receptor (GCGR)
Retatrutide reduced blood pressure, improved lipid profiles, and decreased waist circumference significantly